Blood-Borne Diseases

Previously thought to be difficult or impossible, one study found HCV and drug use can be treated concurrently in young adults.

Dengue is the most prevalent and important mosquito-borne virus in the world. Atea Pharmaceuticals presented positive data for their direct-acting dengue antiviral, AT-752.

Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.

That country is trying to contain the virus to prevent further cases, as well as other African countries met to try to prevent an outbreak inside their own borders.

A new review article suggests it is possible to eradicate hepatitis C virus infections among people with hemophilia, but it will take intense focus from public health agencies.

Hepatitis A infections occurred almost exclusively among adults in states with outbreaks.

“Too few persons are receiving timely treatment” with direct-acting antiviral for hepatitis C based on their first positive test result, the study authors wrote.

Bulevirtide, a first-in-class entry inhibitor, showed promise for the treatment of hepatitis B and hepatitis D coinfection, a phase 2 trial found.

Experts are advocating for occult hepatitis B to be spotlighted.

Uganda’s first Ebola outbreak in a decade raises concern due to its vaccine resistance.

Occult HBV infection is likely to go undetected in under-resourced regions of high HBV endemicity and confound WHO goal to eradicate the viral hepatitis by 2030.

With an all-ready challenging patient population to treat, having a program to get more people into treatment can be helpful in an underserved group.

Among pregnant women coinfected with HIV, a higher hepatitis C viral load increased the likelihood of transmitting HCV to children.

However, according to one study the risk of heart inflammation increases with age and amplifies in patients with hepatitis C (HCV) compared to patients without HCV.

A meta-analysis study shows having the comorbidity presents significant health risks for this patient population.

The same 5-year survival rates with kidney transplants from HCV positive and negative donors supports revising HCV "penalty" in ranking donors.

The Liver Health Initiative’s Thelma King Thiel, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, are a “Dynamic Duo” that are working together to bring about an end to this virus.

Injection drug users who received accessible care treatment at a syringe service program were almost 3 times as likely to complete their hepatitis C treatment than people who received usual care.

Catch up on all the important news and clinical care topics you may have missed this week.

A new report underscores a persistent problem of patients not receiving antivirals despite their high curative rate.

Rates of hepatitis C reinfection were low among people receiving opioid agonist therapy, according to a new study, which highlights the importance of risk reduction interventions and HCV treatment for people who inject drugs and people receiving opioid agonist therapy.

WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.

WHO issues new HCV treatment recommendations that include "radical simplification" of care pathways, in pursuit of testing and treatment goals.

At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.

Implicating adenovirus for hepatitis of unknown cause in children is confounded by its absence in some cases, and from all tested hepatic tissue.

Viral hepatitis “can and should be managed within primary care,” says Dr. Thomas Robertson.

2 patients died of Marburg virus in the southern Ashanti region of Ghana. Nearly 100 close contacts are now under observation for the infectious disease, which is a cousin of the Ebola virus.

The investigational therapy’s data points to a path towards a potential functional cure.

A shorter dosing period and no extra risk of suffering acute myocardial infarction means the newer 2-dose hepatitis B vaccine is an attractive option for protection.

The cases are in the pediatric population and come from 11 countries in the WHO European Region and 1 country in the WHO Region of the Americas.